SCHEMBL4881605

SCHEMBL4881605

Cc1ccc(NC(=O)c2nccnc2C(=O)Nc2ccc(NCCO[Si](C)(C)C(C)(C)C)cc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
RAB9A P51151 7/20 0.42
NPC1 O15118 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 5/20 0.41
RXFP1 Q9HBX9 1/20 0.41
DGAT1 O75907 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TP53 P04637 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALOX15 P16050 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GRM5 P41594 1/20 0.38
CSF1R P07333 1/20 0.38
FLT3 P36888 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4710501 0.89 RAB9A (0.42) KMT2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4886038 0.87 KMT2A (0.40) KMT2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4875148 0.85 RAB9A (0.41) KMT2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4878081 0.83 KMT2A (0.38) KMT2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4882033 0.81 MLYCD (0.42) KMT2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4881556 0.81 MAPT (0.42) RAB9ANPC1SMN1; SMN2MAPTKDM4E
SCHEMBL4873941 0.78 GRM5 (0.40) KMT2ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL14066579 0.78 GRM5 (0.40) KMT2ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL14066580 0.77 MAPT (0.53) KMT2ASMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL3621276 0.77 NPC1 (0.44) KMT2ARAB9ANPC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
EP-1819701-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF Bayer HealthCare AG (DE) 2007-08-22 EP disclosed
WO-2006058630-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 KMT2A 3720/4885RAB9A 2655/4885NPC1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.